[Webinar] How to help scientists accelerate drug design and vaccine development
Delve into how comprehensive predictive science applications can improve structural understanding of viral proteins to design drugs and vaccines
Secure your place to explore how Dassault Systèmes and Janssen Pharmaceutical Companies of Johnson & Johnson are using molecular modeling for drug repurposing, detection of SARS-CoV-2 and vaccine design
The discovery of suitable drugs that could help treat the SARS-CoV-2 virus is a long process – from understanding its epidemiology to resolving its molecular structures, understanding the mechanisms of its druggable protein targets, identifying effective therapeutic agents and finally developing vaccines to prevent further viral spread.
In this Pharma IQ webinar, Dassault Systèmes and Janssen Pharmaceuticals will analyze how computer-aided drug design, simulation and modular design therapeutics are essential analysis tools for speeding up drug development, driving innovation and crucially supporting life science experts in their research to treat the SARS-CoV-2 virus.
Anne Goupil-Lamy, BIOVIA Science Council Fellow at Dassault Systèmes, and Oscar Mendez Lucio, PhD, Scientist - Artificial Intelligence for drug design at The Janssen Pharmaceutical Companies of Johnson & Johnson, will present solution-driven case studies to help maximize drug development profitability and team collaboration.
Join your peers in this interactive webinar and come away with key lessons in how to:
- Leverage an open and scalable platform that brings together over 30 years of peer-reviewed research and world-class in silico techniques
- Understand the benefit of structure-based design workflows
- Increase your understanding of the role of structural vaccinology
- Enhance team collaboration by enabling researchers to better share their data and make better informed decisions in drug development
Sign up now to secure your free place.
Anne Goupil-Lamy, BIOVIA Science Council Fellow, Dassault Systèmes
Oscar Mendez Lucio, PhD, Scientist - Artificial Intelligence for drug design at The Janssen Pharmaceutical Companies of Johnson & Johnson
Oscar got his PhD in Chemistry (cheminformatics) from the University of Cambridge in 2016. In 2017, he joined Bayer to apply deep learning to their research pipeline. Currently, he is a scientist at Janssen Pharmaceuticals using artifical intlligence to automatically design molecules with improved potency and safety profiles. Oscar has published more than 40 scientific papers including some featured in Nature and Nature Communications.
The webinar will take place at:
- 7am PDT
- 10am EDT
- 3pm BST
- 4pm CET